Wednesday, 23 April 2014

and so it goes

Lemtrada is a new trade name - the same drug, Alemtuzumab, is sold as Campath for treatment of lymphomas and lymphocytic leukemia. Campath was pulled from markets in the US and Europe in 2012 to prepare for the higher-priced relaunch as Lemtrada aimed at MS. We're looking at something around $95,000 total for eight treatments over the course of two years. No treatment required after that. Nice price point. 

No comments:

Post a Comment

Please be respectful.